Telix Pharmaceuticals Limited (TLX) is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation.
TLX is headquartered in Melbourne with international operations in Brussels, Kyoto and Indianapolis. It is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.
Telix Pharmaceuticals won AusBiotech's Company Of The Year award in 2022.